Rondaptivon pegol
Based on 1 Customer Validation
Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.20%
- CAS No.: 2573048-75-4
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Rondaptivon pegol (3 μg/mL; 60 min) reduces VWF activity in citrated human plasma to 28.5% of the normal level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rondaptivon pegol (0.1-5.0 mg/kg; intravenous injection; single administration) attenuates acute myocardial ischemia-reperfusion injury in mice by targeting VWF[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6-8 weeks old, wild-type, myocardial ischemia-reperfusion injury model)[2]
-
Dosage:0.1 mg/kg; 0.5 mg/kg; 5.0 mg/kg
-
Administration:i.v.; single dose at reperfusion start
-
Result:Accumulated in ischemic myocardium, inhibited VWF A1 activity, prolonged bleeding time, reduced microvascular obstruction, alleviated inflammatory response and cardiomyocyte apoptosis, significantly decreased infarct size, and improved left ventricular ejection fraction and fractional shortening.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2573048-75-4
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Rondaptivon pegol]
-
Synonyms
BT200
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
H2O : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (1518 KB)
Références
[1]. Zhu S, Gilbert JC, Liang Z, et al. Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200. J Thromb Haemost. 2020;18(7):1695-1704. [Content Brief]
[2]. Chen X, et al. Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice. J Thromb Haemost. 2025;23(1):222-234. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rondaptivon pegol Related Classifications
HY-153999 Related Classifications
Powered by Bioz